BioSpace News Archive

DURECT Corporation announced financial results for the three months ended June 30, 2020 and provided a corporate update.

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced members of the executive team will present during upcoming virtual investor conferences.

Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that the company will participate in the following August investor conferences

Avinger, Inc. announced the pricing of an underwritten public offering with gross proceeds to the Company expected to be approximately $6 million before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company.

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) today announced that new clinical and experimental pharmacology data for its lead drug candidate ATH434 (formerly PBT434) has been selected for presentation at the 2020 International Congress of Parkinson’s Disease and Movement Disorders (MDS 2020) and the American Neurological Association’s 2020 Annual Meeting (ANA 2020).

ORIC Pharmaceuticals, Inc., a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced that management will host a conference call and webcast to discuss its second quarter 2020 financial results and other business highlights on Wednesday, August 5, 2020, at 4:30 p.m. ET.

Amcor plc will announce its full year results for the twelve months ended 30 June 2020 before the US market opens at 3.00am US Eastern Daylight Time / 5.00 pm Australian Eastern Standard Time on Tuesday 18 August 2020.

ArisGlobal, the leading provider of life sciences software that automates drug development functions for over 300 life sciences companies, today announced that a large, top five global biopharmaceutical company has selected its LifeSphere MultiVigilance safety system as the foundation of its next-generation pharmacovigilance technology environment. I

Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, is very pleased that the Sean M Healey & AMG Center for ALS at Mass General announced the first patients have been enrolled into the HEALEY ALS Platform Trial being conducted at sites of the Northeast ALS (NEALS) consortium.

Rx-360, an international pharmaceutical consortium dedicated to supply chain integrity and patient safety is very excited to announce the expansion of its Audit Program